Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
about
Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticusCa(2+) signalling by recombinant human CXCR2 chemokine receptors is potentiated by P2Y nucleotide receptors in HEK cellsFunctional expression of CCR2 by human fetal astrocytesDeubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativationRole of microglia in central nervous system infectionsTau-tubulin kinaseThe role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systemsNeuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptorsInflammation and Alzheimer's diseaseMechanisms of mononuclear phagocyte recruitment in Alzheimer's diseaseNetwork Topology Analysis of Post-Mortem Brain Microarrays Identifies More Alzheimer's Related Genes and MicroRNAs and Points to Novel Routes for Fighting with the DiseaseNeuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's diseaseRole of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptideMicrofluidic chemotaxis platform for differentiating the roles of soluble and bound amyloid-β on microglial accumulation.Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid-β.RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.MCP-1 and CCR2 contribute to non-lymphocyte-mediated brain disease induced by Fr98 polytropic retrovirus infection in mice: role for astrocytes in retroviral neuropathogenesis.Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.Correlation between serum RANTES levels and the severity of Parkinson's disease.Slit proteins, potential endogenous modulators of inflammation.Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammationTargeting monocyte chemoattractant protein-1 signalling in disease.Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid depositionA potential role for CXCR3 chemokines in the response to ocular HSV infection.MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age.Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity.Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's diseasePharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease.Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseasesIdentification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression.Elevated plasma MCP-1 concentration following traumatic brain injury as a potential "predisposition" factor associated with an increased risk for subsequent development of Alzheimer's disease.Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxiaRole of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approachesAltered distribution of cell cycle transcriptional regulators during Alzheimer disease.Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissuesCCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function.AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.
P2860
Q21245234-9313B8A2-AAF6-4C12-A7DD-DBED690CC338Q24292394-D051DF62-6E1F-4A75-9F64-1805032A9724Q24307605-F8B6C44A-EEC8-4098-8322-06C1F532F786Q24310461-36104D49-4E5F-4687-B1FB-95B735070B87Q24563024-50693E73-85B6-4D3B-B64E-72EEBB82B3E1Q26829288-A7CA8352-3A35-4309-8596-68767E6C6B49Q26861263-B21E9608-8163-4839-8B69-C1C77B94CD1CQ26992010-1D7694D9-75EA-4250-BE45-05E823FFE194Q26995483-6DB12A86-9646-424A-906D-90FA3DA6B65BQ28138617-DA12B042-39A8-49C7-A3FD-1AD94B48E781Q28275105-A20C4D16-D087-4A20-AB5D-2188A76C82EBQ28552595-CE7A4BF3-FEE6-4DD6-BD86-AD6E263F665BQ30054419-9627BF91-851A-4A1C-B129-4132B9797296Q30490518-44BD0E07-4EF3-49B9-8FE9-33A4CE1ED045Q30539682-D6DF7F73-D183-4EDA-AD04-105C69957060Q33359453-3F096D13-3997-43C3-BAEF-A8AD384ADF62Q33578739-15EADA13-0469-4481-A3C8-E84A614E3DAEQ33856674-7D0B61DC-9C8E-4035-99E3-43CB4DD8F5FBQ34161535-C8CCE72E-1D7A-418A-80E3-ED5A5062A2A2Q34192523-92890AF7-0463-41AE-85D8-EB0D70AE2AEFQ34784469-2E0B1FA3-DEB6-44ED-A275-090AE068B9D3Q34813794-363C92B8-204A-4DF3-855C-9EF273F9C107Q35022576-8CB954B4-A90B-4B85-B878-BD39BB9A7F01Q35025065-62A2B69A-13D9-44DE-AB17-FE1DE9C4F401Q35056023-C190F69D-077C-41AC-BF8C-5D0B4F38024AQ35087794-9A948A9C-D8DF-4BDB-A43D-E56DD4E745F7Q35158048-893A2B96-01D6-47F2-99EC-2F32BB4BA2DFQ35192124-F6CD29F9-C4BA-445B-945E-E079EFAD19E2Q35607881-379D7862-A841-48B6-A24C-421CA1938502Q35846770-E5E4A1F2-22DB-4C22-962A-3AC3FE1916CAQ35931230-615FE5E6-6414-4286-A9B6-3FC65375B381Q36023238-2E526AC4-46EC-48A0-BD02-40F384EC7372Q36546976-A3D3D0E3-A39B-454F-8F31-F19FCEFFD20FQ36622309-85908C98-EC6C-43EF-B125-E7271E4DF8C7Q36828651-866294AB-9D21-4A77-B142-9EB7C12FB256Q36830938-933AA22F-9415-411E-880F-EBAFE7D1233EQ36931808-C9EB3EE1-7579-458E-BFAB-5399ED963C8BQ36932117-DBEAE165-A8E5-4A3F-98E5-56827B333E3CQ37022079-B14CAE7A-5065-41A0-ADD9-D6E0A8B9C26CQ37260178-FD820AD3-22C4-4E73-9990-7C5576B8B134
P2860
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@ast
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@en
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@nl
type
label
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@ast
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@en
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@nl
prefLabel
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@ast
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@en
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@nl
P1476
Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease.
@en
P2888
P356
10.3109/13550289909029743
P577
1999-02-01T00:00:00Z
P5875
P6179
1070986145